For the second quarter of 2026, analysts anticipate Beam Therapeutics will report revenue of $315.40 million and earnings per share of $1.00, while the current stock price of $34.50 remains significantly below the $52.00 average analyst price target. The primary focus for investors during this earnings call is the clinical data update from the BEACON trial evaluating BEAM-101 in patients with sickle cell disease.
Market participants are specifically looking for evidence of durable fetal hemoglobin induction and a differentiated safety profile compared to first-generation gene-editing treatments. Maintaining a disciplined cash runway through 2027 while advancing the BEAM-302 regulatory filing remains a critical component of the company's long-term valuation narrative.